'Still Bad Out There' - Drug Makers In APAC Prepare For Worst Before It Gets Better
Decoupling Forces Diversification, Evolution
Cross-border deals are down and investment has dried up, while geopolitical tensions have started hitting the Chinese biotech sector in unprecedented ways. Biopharma firms are expecting more rainy days ahead and are embracing new fundraising and deal-making approaches to survive and thrive.
